Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases

MT Newswires Live09-10

Carisma Therapeutics (CARM) said Tuesday it is expanding its collaboration with Moderna (MRNA) to include the nomination of two targets to treat autoimmune diseases.

The companies will develop in vivo chimeric antigen receptor macrophage and monocyte or CAR-M for autoimmune diseases, building on preclinical in vivo CAR-M data in oncology, Carisma said.

Carisma said Moderna nominated two autoimmune disease targets under the collaboration, which will use Carisma's CAR-M technology and Moderna's mRNA/LNP platform for the development of in vivo macrophage engineering approaches in the nominated targets.

Beyond the two nominated targets, which will be exclusively partnered with Moderna, all rights in autoimmune disease will be retained by Carisma, according to Carisma.

Carisma, which will have the responsibility to discover and optimize development candidates, said it will receive research funding and can get development, regulatory and commercial milestone payments, as well as royalties on net sales of any products commercialized under the deal.

The clinical development and commercialization of therapeutics resulting from the deal will be led by Moderna, Carisma said.

Price: 1.0300, Change: +0.02, Percent Change: +1.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466430320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466430320","market":"sh","top_or_hot":-1,"title":"Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CARM\">Carisma Therapeutics</a> (CARM) said Tuesday it is expanding its collaboration with Moderna (MRNA) to include the nomination of two targets to treat autoimmune diseases.</p><p>The companies will develop in vivo chimeric antigen receptor macrophage and monocyte or CAR-M for autoimmune diseases, building on preclinical in vivo CAR-M data in oncology, Carisma said.</p><p>Carisma said Moderna nominated two autoimmune disease targets under the collaboration, which will use Carisma's CAR-M technology and Moderna's mRNA/LNP platform for the development of in vivo macrophage engineering approaches in the nominated targets.</p><p>Beyond the two nominated targets, which will be exclusively partnered with Moderna, all rights in autoimmune disease will be retained by Carisma, according to Carisma.</p><p>Carisma, which will have the responsibility to discover and optimize development candidates, said it will receive research funding and can get development, regulatory and commercial milestone payments, as well as royalties on net sales of any products commercialized under the deal.</p><p>The clinical development and commercialization of therapeutics resulting from the deal will be led by Moderna, Carisma said.</p><p>Price: 1.0300, Change: +0.02, Percent Change: +1.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCarisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Carisma Therapeutics (CARM) said Tuesday it is expanding its collaboration with Moderna (MRNA) to include the nomination of two targets to treat autoimmune diseases.The companies will develop in vivo ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466430320","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466430320","pubTimestamp":1725972679,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Carisma Therapeutics  said Tuesday it is expanding its collaboration with Moderna  to include the nomination of two targets to treat autoimmune diseases.The companies will develop in vivo chimeric antigen receptor macrophage and monocyte or CAR-M for autoimmune diseases, building on preclinical in vivo CAR-M data in oncology, Carisma said.Carisma said Moderna nominated two autoimmune disease targets under the collaboration, which will use Carisma's CAR-M technology and Moderna's mRNA/LNP platform for the development of in vivo macrophage engineering approaches in the nominated targets.Beyond the two nominated targets, which will be exclusively partnered with Moderna, all rights in autoimmune disease will be retained by Carisma, according to Carisma.Carisma, which will have the responsibility to discover and optimize development candidates, said it will receive research funding and can get development, regulatory and commercial milestone payments, as well as royalties on net sales of an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4568":"美国抗疫概念","BK4532":"文艺复兴科技持仓","BK4588":"碎股","CARM":"Carisma Therapeutics","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","MRNA":"Moderna, Inc."},"translate_title":"Carisma Therapeutics与Moderna将合作扩大到自身免疫性疾病领域","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARM":1,"MRNA":0.7},"content_text":"Carisma Therapeutics (CARM) said Tuesday it is expanding its collaboration with Moderna (MRNA) to include the nomination of two targets to treat autoimmune diseases.The companies will develop in vivo chimeric antigen receptor macrophage and monocyte or CAR-M for autoimmune diseases, building on preclinical in vivo CAR-M data in oncology, Carisma said.Carisma said Moderna nominated two autoimmune disease targets under the collaboration, which will use Carisma's CAR-M technology and Moderna's mRNA/LNP platform for the development of in vivo macrophage engineering approaches in the nominated targets.Beyond the two nominated targets, which will be exclusively partnered with Moderna, all rights in autoimmune disease will be retained by Carisma, according to Carisma.Carisma, which will have the responsibility to discover and optimize development candidates, said it will receive research funding and can get development, regulatory and commercial milestone payments, as well as royalties on net sales of any products commercialized under the deal.The clinical development and commercialization of therapeutics resulting from the deal will be led by Moderna, Carisma said.Price: 1.0300, Change: +0.02, Percent Change: +1.98","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466430320"}